Updates are available Erratum dated 2025-09-26

Article History

Accepted: 27 November 2024

First Online: 17 June 2025

Change Date: 27 August 2025

Change Type: Update

Change Details: The original online version of this article was revised: In Table 3 of this article, entries in the second column / heading “Drug treatment / Acute phase/symptomatic” were incorrect. The text was incorrecty given as “May be considered: antiemetics (domperidone, metoclopramide, ondansetron) and/or antivertiginous drugs (cinnarizine± dimenhydrinate) for a max. of 2–3 days, Ginkgo biloba extract (EGb 716) to support central adaptation [28, 29]” but should have been “May be considered: antiemetics (domperidone, metoclopramide, ondansetron) and/or antivertiginous drugs (cinnarizine± dimenhydrinate) for a max. of 2–3 days, Ginkgo biloba extract (EGb 761) to support central adaptation [28, 29]”

Change Details: Supplementary file: In Table S1, Term “Acute imbalance syndrome (AIS)” the Definition should have read „…without spontaneous or gaze-evoked nystagmus” instead of “…with spontaneous or gaze-evoked nystagmus” .

Change Date: 26 September 2025

Change Type: Erratum

Change Details: An Erratum to this paper has been published:

Change Details: https://doi.org/10.1007/s00106-025-01670-9

Declarations

:

: This study was financially supported by Schwabe Pharma AG (coverage of costs for drawing figures by H + O communications; paid lectures to several authors at an advisory board reporting study results). The selection of the contents of this guidance paper and the article writing were done solely by the authors. The content of this guidance paper reflects the authors’ opinion. Both Schwabe Pharma AG and H + O communications had no impact on the content of this paper. There was also no medical writing involved. Furthermore, the authors declare: A.A. Tarnutzer: Financial interests: lecturing honoraria from “Forum für medizinische Fortbildung” (FomF), Diatec, Schwabe Pharma AG and Hennig Pharmaceuticals and coverage of costs for travel and accommodation by Diatec, Schwabe Pharma AG and Hennig Pharmaceuticals. Non-financial interests: Member of the executive board of the Swiss Neurological Society (SNS). H. Kerkeni, C. Candreia, R. Piantanida and A. Welge-Lüssen: Financial interests: lecturing honorarium and coverage of costs for travel and accommodation from Schwabe Pharma AG. S. Diener, R. Kalla, R. Maire and J. Budweg. Financial interests: lecturing honorarium from Schwabe Pharma AG. A. Zwergal: Financial interests: grant support by the European Union (MSCA project PROVIDE), “Cures within reach” and by the innovation fund of the “Gemeinsamer Bundesausschuss” (Project “PoiSe”). Lecturing honoraria from Schwabe Pharma AG, Pfizer and Astra Zeneca; participation in an advisory board of the Dr. Willmar Schwabe GmbH; Non-financial interests: speaker of the commission “Neuroophthalmologie/Neurootologie” in the German Neurological Society (DGN). J. Dlugaiczyk: Financial interests: lecturing honoraria from “Forum für medizinische Fortbildung” (FomF), Diatec, Schwabe Pharma AG and Hennig Pharmaceuticals and coverage of costs for travel and accommodation by Diatec, Schwabe Pharma AG and Hennig Pharmaceuticals. Non-financial interests: Member of the executive board of the working group of German-speaking Audiologists, Neurotologists and Otologists (ADANO) and of the Prosper Menière Society; Editorial Board Member HNO, Review Editor Frontiers in Neurology.

: This article does not contain any studies with human participants or animals performed by any of the authors.

: The supplement containing this article is not sponsored by industry.